Skip to main content
Clinical Trials/NL-OMON37670
NL-OMON37670
Completed
Not Applicable

Towards plannable breast surgery: diagnostic accuracy of microbubble enhanced Iodine-125 seed localization of the sentinel lymph node (MIB study) - Microbubbles and Iodine seeds in Breast cancer: MIB study

niversitair Medisch Centrum Utrecht0 sites120 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
breast cancer
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
120
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • \- Females, aged 18 years or older
  • \- Histologically confirmed invasive carcinoma or patients with in situ breast cancer with indication for SLN biopsy

Exclusion Criteria

  • \- Male patients
  • \- Histologically or cytologically proven axillary lymph node involvement
  • \- Recurrent disease
  • \- Indication for ALND
  • \- Pregnancy or lactation
  • \- Sentinel lymph node biopsy after neoadjuvant treatment
  • \- Recent acute coronary syndrome or unstable ischemic heart disease\*
  • \- Severe lung disease\* and shortness of breath
  • \- Unstable neurologic disease, acute endocarditis, artificial heart valves, acute systemic infection, tromboembolic disease, advanced liver or kidney failure
  • \- Mentally incompetent patients;\* SonoVue is contraindicated in patients known to have right\-to\-left shunts, severe pulmonary hypertension (pulmonary artery pressure \>90 mmHg, uncontrolled systemic hypertension, and in patients with adult respiratory distress syndrome. Caution is advised when SonoVue is administered to patients with clinically significant pulmonary disease, including severe chronic obstructive pulmonary disease.

Outcomes

Primary Outcomes

Not specified

Similar Trials